Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Results of a Phase 1 Clinical Trial of Allogeneic Tumor-Primed Natural Killer Cells in AML

Panagiotis Kottaridis, MD, PhD, Maria Tsirogianni, MD, Janet North, BSc, MSc, Chloe Marden, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath

Blood (2011) 118 (21): 946.

https://doi.org/10.1182/blood.V118.21.946.946

Published: 2011

Journal Articles

CMV-Reactive T Cells Can Be Isolated From G-CSF Mobilised Peripheral Blood Apheresates.

Edward R Samuel, MSc, Katy Newton, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath

Blood (2010) 116 (21): 1276.

https://doi.org/10.1182/blood.V116.21.1276.1276

Published: 2010

Journal Articles

CMV-Reactive γ/δ T Cells Are Equivalent to Their α/β Counterparts In the Lysis of CMV-Infected Targets – Potential for Post Transplant Adoptive Immunotherapy.

Andrea Knight, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath

Blood (2010) 116 (21): 1277.

https://doi.org/10.1182/blood.V116.21.1277.1277

Published: 2010

Journal Articles

Adoptive Transfer of CMV-Specific Donor T Cells Following Allogeneic Transplantation Leads to Rapid and Safe Systemic Reconstitution.

Karl S Peggs, MD, Kirsty Thomson, MD, Edward Samuel, BSc, MSc, Gemma Dyer, Julie Armoogum, Kwok Pang, BSc, MSc, Ronjon Chakraverty, MD, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath

Blood (2009) 114 (22): 44.

https://doi.org/10.1182/blood.V114.22.44.44

Published: 2009

Journal Articles

CMV-Reactive Gamma/Delta T Cells Expanded From CMV Seronegative Normal Healthy Individuals Lyse CMV-Infected Targets – Potential Adoptive Immunotherapy for Recipients of Stem Cell Transplants From CMV Seronegative Donors.

Andrea Knight, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath

Blood (2009) 114 (22): 2233.

https://doi.org/10.1182/blood.V114.22.2233.2233

Published: 2009

Journal Articles

A Phase I/II Clinical Trial of Tumour-Activated Allogeneic Natural Killer Cells in AML

Panos Kottaridis, Janet North, Ismail Bakhsh, Edward Samuel, Stephen Mackinnon, Mark W Lowdell, PhD, FRCPath

Blood (2008) 112 (11): 2901.

https://doi.org/10.1182/blood.V112.11.2901.2901

Published: 2008

NARROW

Results of a Phase 1 Clinical Trial of Allogeneic Tumor-Primed Natural Killer Cells in AML

CMV-Reactive T Cells Can Be Isolated From G-CSF Mobilised Peripheral Blood Apheresates.

CMV-Reactive γ/δ T Cells Are Equivalent to Their α/β Counterparts In the Lysis of CMV-Infected Targets – Potential for Post Transplant Adoptive Immunotherapy.

Adoptive Transfer of CMV-Specific Donor T Cells Following Allogeneic Transplantation Leads to Rapid and Safe Systemic Reconstitution.

CMV-Reactive Gamma/Delta T Cells Expanded From CMV Seronegative Normal Healthy Individuals Lyse CMV-Infected Targets – Potential Adoptive Immunotherapy for Recipients of Stem Cell Transplants From CMV Seronegative Donors.

A Phase I/II Clinical Trial of Tumour-Activated Allogeneic Natural Killer Cells in AML

Email alerts

ASH Publications

American Society of Hematology

Results of a Phase 1 Clinical Trial of Allogeneic Tumor-Primed Natural Killer Cells in AML

CMV-Reactive T Cells Can Be Isolated From G-CSF Mobilised Peripheral Blood Apheresates.

CMV-Reactive γ/δ T Cells Are Equivalent to Their α/β Counterparts In the Lysis of CMV-Infected Targets – Potential for Post Transplant Adoptive Immunotherapy.

Adoptive Transfer of CMV-Specific Donor T Cells Following Allogeneic Transplantation Leads to Rapid and Safe Systemic Reconstitution.

CMV-Reactive Gamma/Delta T Cells Expanded From CMV Seronegative Normal Healthy Individuals Lyse CMV-Infected Targets – Potential Adoptive Immunotherapy for Recipients of Stem Cell Transplants From CMV Seronegative Donors.

A Phase I/II Clinical Trial of Tumour-Activated Allogeneic Natural Killer Cells in AML

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only